A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third- Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor and Ibrutinib in Patients with B-cell Malignancies.
The goal of this clinical research study is to learn the highest tolerable dose of the combination of ublituximab and TGR-1202 (umbralisib) or the combination of ublituximab, umbralisib, and ibrutinib that can be given to patients with B-cell lymphoma or leukemia. The safety of this study drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 08/21/2014
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: